Preliminary phase 2 results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate cancer patients

被引：0
|
作者：
Cook, Natalie
Bernard-Tessier, Alice
Barthelemy, Philippe
Utriainen, Tapio
Roubaud, Guilhem
Flechon, Aude
van der Voet, Hans
Gravis Mescam, Gwenaelle
Ratta, Raffaele
Jones, Rob
Parikh, Omi
Tanner, Minna
Garratt, Chris
Nevalaita, Liina
Pohjanjousi, Pasi
Ikonen, Tarja
Antonarakis, Emmanuel
Fizazi, Karim
机构：
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs57
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [1] Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients
    Fizazi, K.
    Bernard-Tessier, A.
    Barthelemy, P.
    Utriainen, T.
    Roubaud, G.
    Flechon, A.
    van der Voet, J. C. M.
    Mescam, G. Gravis
    Ratta, R.
    Jones, R. H.
    Parikh, O. A.
    Tanner, M. M. E.
    Garratt, C.
    Nevalaita, L.
    Pohjanjousi, P.
    Ikonen, T.
    Antonarakis, E. S.
    Cook, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1165
  • [2] Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
    Fizazi, Karim
    Cook, Natalie
    Barthelemy, Philippe
    Bernard-Tessier, Alice
    Baldini, Capucine
    Peters, Niamh
    Nykanen, Pirjo
    Ikonen, Tarja
    Pohjanjousi, Pasi
    Mattila, Leena
    Jouhi, Lauri
    Vuorela, Annamari
    Garratt, Chris
    Utriainen, Tapio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
    Fizazi, K.
    Roubaud, G.
    Bernard-Tessier, A.
    Gravis, G.
    Flechon, A.
    Ratta, R.
    Barthelemy, P.
    Jones, R. J.
    Parikh, O. A.
    Hussain, A.
    van der Voet, J. C. M.
    Cook, N.
    Tanner, M. M. E.
    Jones, R. H.
    Garratt, C.
    Ikonen, T.
    Pohjanjousi, P.
    Poehlein, C. H.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S968 - S968
  • [4] MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.
    Fizazi, Karim
    Roubaud, Guilhem
    Bernard-Tessier, Alice
    Gravis, Gwenaelle
    Flechon, Aude
    Ratta, Raffaele
    Barthelemy, Philippe
    Jones, Robert J.
    Parikh, Omi
    Hussain, Arif
    van der Voet, Hans
    Cook, Natalie
    Peters, Niamh
    Tanner, Minna
    Jones, Robert Hugh
    Garratt, Chris
    Pohjanjousi, Pasi
    Ikonen, Tarja
    Poehlein, Christian Heinrich
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 159 - 159
  • [5] ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
    Oksala, R.
    Karimaa, M.
    Ramela, M.
    Riikonen, R.
    Huhtaniemi, R.
    Rummakko, P.
    Wohlfahrt, G.
    Vuorela, A.
    Mustonen, M. V.
    Kallio, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [7] Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
    Yu, Evan Y.
    Wilding, George
    Posadas, Edwin
    Gross, Mitchell
    Culine, Stephane
    Massard, Christophe
    Morris, Michael J.
    Hudes, Gary
    Calabro, Fabio
    Cheng, Shinta
    Trudel, Geralyn C.
    Paliwal, Prashni
    Sternberg, Cora N.
    CLINICAL CANCER RESEARCH, 2009, 15 (23) : 7421 - 7428
  • [8] Results of phase 2 study of [177Lu]Ludotadipep for metastatic castration-resistant prostate cancer
    Kwon, S.
    Lee, J.
    Park, C.
    Min, J.
    Ha, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S328 - S328
  • [9] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [10] CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer
    Smith, Matthew Raymond
    Piulats, Josep M.
    Todenhofer, Tilman
    Lee, Jae-Lyun
    Arija, Jose Angel Arranz
    Mazilu, Laura
    Azad, Arun
    Alonso-Gordoa, Teresa
    McGovern, Ursula Brigid
    Choudhury, Atish Dipankar
    Ye, Dingwei
    Suzuki, Hiroyoshi
    Mckay, Rana R.
    Ades, Steven
    Flechon, Aude
    Pieczonka, Christopher Michael
    Hulstijn, Maarten
    Lithio, Andrew
    Nacerddine, Karim
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345